IMARA(IMRA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Pipeline Updates ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). • Completed dosing in Phase 1b randomized portion of ongoing ENABLE clinical trial evaluating ELVN- 001 in patients with CML (NCT05304377). • Presented encore data from the ENABLE Phase 1a/1b clinical trial of ELVN-001 at several medical meetings, including: o An oral and poster p ...